Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid

International Journal of Oncology

Volumn 27, Issue 3, 2005, Pages 823-830

  Qiu, Lihua ^a   Wang, Qun ^b   Di, Wen ^a   Jiang, Qin ^c   Schefeller, Erica ^d   Derby, Steve ^d   Wanebo, Harold ^e   Yan, Bingfang ^f   Wan, Yin Sheng ^d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Guangdong Provincial Peoples Hospital   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d PROVIDENCE COLLEGE   (United States)

^e ROGER WILLIAMS MEDICAL CENTER   (United States)

^f UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

AKT; Betulinic acid; Epithelial growth factor receptor; Melanoma; Survivin

Indexed keywords

4 ((3 BROMOPHENYL)AMINO) 6,7 DIMETHOXYQUINAZOLINE; 4-((3-BROMOPHENYL)AMINO)-6,7-DIMETHOXYQUINAZOLINE; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BETULIC ACID; BIRC5 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE; TRITERPENE; TUMOR PROTEIN;

ANIMAL; ARTICLE; CELL CULTURE; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; EMBRYO; FIBROBLAST; GENETICS; HUMAN; KERATINOCYTE; MELANOMA; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EMBRYO; EPIDERMAL GROWTH FACTOR; FIBROBLASTS; HUMANS; KERATINOCYTES; MELANOMA; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TRITERPENES;

EID: 24344483143     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Grossman D and Altieri DC: Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 20: 3-11, 2001.
2. Schaffer JV, Rigel DS, Kopf AW and Bolognia JL: Cutaneous melanoma - past, present, and future. J Am Acad Dermatol 51: S65-69, 2004.
3. Young AR: Tanning devices - fast track to skin cancer? Pigment Cell Res 17: 2-9, 2004.
4. Kalkman E and Baxter G: Melanoma. Clin Radiol 59: 313-326, 2004.
5. Florez A and Cruces M: Melanoma epidemic: true or false? Int J Dermatol 43: 405-407, 2004.
6. Hersey P and Zhang XD: How melanoma cells evade trailinduced apoptosis. Nat Rev Cancer 1: 142-150, 2001.
7. Soengas MS and Lowe SW: Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151, 2003.
8. Perlis C and Herlyn M: Recent advances in melanoma biology. Oncologist 9: 182-187, 2004.
9. Satyamoorthy K, Bogenrieder T and Herlyn M: No longer a molecular black box - new clues to apoptosis and drug resistance in melanoma. Trends Mol Med 7: 191-194, 2001.
10. Leenders WP, Kusters B, Verrijp K, Maass C, Wesseling P, Heerschap A, Ruiter D, Ryan A and de Waal R: Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10: 6222-6230, 2004.
11. Itoh S, Hattori T, Hayashi H, Mizutani Y, Todo M, Takii T, Yang D, Lee JC, Matsufuji S, Murakami Y, Chiba T and Onozaki K: Antiproliferative effect of IL-1 is mediated by p38 mitogen-activated protein kinase in human melanoma cell A375. J Immunol 162: 7434-7440, 1999.
12. Ravindranath MH, Muthugounder S, Presser N and Viswanathan S: Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol 546: 121-165, 2004.
13. Chen Y, Kramer DL, Diegelman P, Vujcic S and Porter CW: Apoptotic signaling in polyamine analogue-treated SKMEL- 28 human melanoma cells. Cancer Res 61: 6437-6444, 2001.
14. Ivanov VN and Hei TK: Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem 279: 22747-22758, 2004.
15. Merighi S, Mirandola P, Varani K, Gessi S, Capitani S, Leung E, Baraldi PG, Tabrizi MA and Borea PA: Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemotherapic drugs: taxol and vindesine. Biochem Pharmacol 66: 739-748, 2003.
16. Liu T, Brouha B and Grossman D: Rapid induction of mitochondrial events and caspase-independent apoptosis in survivin-targeted melanoma cells. Oncogene 23: 39-48, 2004.
17. Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, Beecher CW, Fong HH, Kinghorn AD, Brown DM, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Medl: 1046-1051, 1995.
18. Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, lansen B and Kodym R: Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 114: 935-940, 2000.
19. Sawada N, Kataoka K, Kondo K, Arimochi H, Fujino H, Takahashi Y, Miyoshi T, Kuwahara T, Monden Y and Ohnishi Y: Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. Br I Cancer 90: 1672-1678, 2004.
20. Eiznhamer DA and Xu ZQ: Betulinic acid: a promising anticancer candidate. Drugs 7: 359-373, 2004.
21. Tan Y, Yu R and Pezzuto JM: Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin Cancer Res 9: 2866-2875, 2003.
22. Zuco V, Supino R, Righetti SC, Cleris L, Marchesi E, Gambacorti-Passerini C and Formelli F: Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett 175: 17-25,2002.
23. Cichewicz RH and Kouzi SA: Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev 24: 90-114,2004.
24. Fulda S, Jeremias I, Pietsch T and Debatin KM: Betulinic acid: a new chemotherapeutic agent in the treatment of neuroectodermal tumors. Klin Padiatr 211: 319-322, 1999.
25. Fulda S, Jeremias I, Steiner HH, Pietsch T and Debatin KM: Betulinic acid: a new cytotoxic agent against malignant brain tumor cells. Int J Cancer 82: 435-441, 1999.
26. Schmidt ML, Kuzmanoff KL, Ling-Indeck L and Pezzuto JM: Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer 33: 2007-2010, 1997.
27. Wick W, Grimmel C, Wagenknecht B, Dichgans J and Weller M: Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther 289:1306-1312,1999.
28. Ehrhardt H, Fulda S, Fuhrer M, Debatin KM and Jeremias I: Betulinic acid-induced apoptosis in leukemia cells. Leukemia 18:1406-1412,2004.
29. Gradilone A, Gazzaniga P, Ribuffo D, Scarpa S, Cigna E, Vasaturo F, Bottom U, Innocenzi D, Calvieri S, Scuderi N, Frati L and Agliano AM: Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J Clin Oncol 21:306-312,2003.
30. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK and Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884-2890, 1999.
31. Wan YS, Wang ZQ, Shao Y, Voorhees JJ and Fisher GJ: Ultraviolet irradiation activates PI 3-kinase/AKT survival pathway via EGF receptors in human skin in vivo. Int J Oncol 18: 461-466, 2001.
32. Ivanov VN and Hei TK: Combined treatment with EGFR inhibitors and arsenite up-regulated apoptosis in human EGFRpositive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene 24: 616-626, 2004.
33. Fran J, Master Z, Yu JL, Rak J, Dumont DJ and Kerbel RS: A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 99: 4349-54, 2002.
34. Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O'Connor DS, Li F, Altieri DC and Sessa WC: Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 275: 9102-9105, 2000.
35. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer PH, Peter ME and Debatin KM: Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57: 4956-4964, 1997.
36. Hata K, Hori K and Takahashi S: Differentiation- and apoptosis-inducing activities by pentacyclic triterpenes on a mouse melanoma cell line. J Nat Prod 65: 645-648, 2002.
37. Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomasovic B, Brock WA, Ajani JA and Kelly AM: Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 47: 403-406, 1987.
38. Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B and Herlyn M: Constitutive expression of multiple growth factor genes by melanoma cells, but not normal melanocytes. J Invest Dermatol 97: 20-26, 1991.
39. Ning S, Shui C, Khan WB, Benson W, Lacey DL and Knox SJ: Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 40: 177-187, 1998.
40. Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, Berwick M and Gruber SB: EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res 64: 2668-2672, 2004.
41. Kondo S, Hozumi Y and Aso K: Autocrine secretion of an EGFlike substance by a cell line (HSC-1) derived from a human skin squamous cell carcinoma. J Dermatol Sci 2: 161-165, 1991.
42. Sauvaigo S, Fretts RE, Riopelle RJ and Lagarde AE: Autonomous proliferation of MeWo human melanoma cell lines in serum-free medium: secretion of growth-stimulating activities. Int J Cancer 37: 123-132, 1986.
43. Mueller BM, Romerdahl CA, Trent JM and Reisfeld RA: Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor. Cancer Res 51: 2193-2198, 1991.
44. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA and Mueller BM: Therapeutic potential of chimeric and murine antiepidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 37: 343-349, 1993.
45. Xu G, Zhang W, Bertram P, Zheng XF and McLeod H: Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24: 893-900, 2004.
46. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R and Rapp UR: Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6-18, 2004.
47. Wan Y, Wang Z, Shao Y, Xu Y, Voorhees J and Fisher G: UVinduced expression of GADD45 is mediated by an oxidantsensitive pathway in cultured human keratinocytes and in human skin in vivo. Int J Mol Med 6: 683-688, 2000.
48. Zhang XD, Borrow JM, Zhang XY, Nguyen T and Hersey P: Activation of ERK1/2 protects melanoma cells from TRAILinduced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22: 2869-2881, 2003.
49. Tague SE, Muralidharan V and D'Souza-Schorey C: ADPribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci USA 101: 9671-9676, 2004.
50. Triscjuoglio D, Iervolino A, Candiloro A, Fibbi G, Fanciulli M, Zangemeister-Wittke U, Zupi G and Del Bufalo D: bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Spl activation: involvement of ERK1/ERK2 activity. J Biol Chem 279: 6737-6745, 2004.
51. Jiang K, Sun J, Cheng J, Djeu JY, Wei S and Sebti S: Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Mol Cell Biol 24: 5565-5576, 2004.
52. Aguirre-Ghiso JA, Estrada Y, Liu D and Ossowski L: ERK (MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38 (SAPK). Cancer Res 63: 1684-1695, 2003.
53. Poon KH, Zhang J, Wang C, Tse AK, Wan CK and Fong WF: Betulinic acid enhances lalpha,25-dihydroxyvitamin D3-induced differentiation in human HL-60 promyelocytic leukemia cells. Anticancer Drugs 15:619-624, 2004.
54. Smalley KS: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104: 527-532, 2003.
55. Schuierer MM, Bataille F, Hagan S, Kolch W and Bosserhoff AK: Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 64: 5186-5192, 2004.
56. Krasilnikov M, Ivanov VN, Dong J and Ronai Z: ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22: 4092-4101, 2003.
57. Um JH, Kwon JK, Kang CD, Kim MJ, Ju DS, Bae JH, Kim DW, Chung BS and Kim SH: Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNAdependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J Pharmacol Exp Ther 311:1062-1070, 2004.
58. Ma D and Niederkorn JY: Role of epidermal growth factor receptor in the metastasis of intraocular melanomas. Invest Ophthalmol Vis Sci 39: 1067-1075, 1998.
59. Selzer E, Thallinger C, Hoeller C, Oberkleiner P, Wacheck V, Pehamberger H and Jansen B: Betulinic acid-induced Mcl-1 expression in human melanoma - mode of action and functional significance. Mol Med 8: 877-884, 2002.
60. Hussein MR, Haemel AK and Wood GS: Apoptosis and melanoma: molecular mechanisms. J Pathol 199: 275-288, 2003.
61. Grossman D, McNiff JM, Li F and Altieri DC: Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113: 1076-1081, 1999.
62. Fulda S and Debatin KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64: 337-346, 2004.
63. Grossman D, Kim PJ, Scheduler JS and Altieri DC: Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98: 635-640, 2001.
64. Pennati M, Binda M, Colella G, Folini M, Citti L, Villa R, Daidone MG and Zaffaroni N: Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 120: 648-654, 2003.
65. Pennati M, Binda M, De Cesare M, Pratesi G, Folini M, Citti L, Daidone MG, Zunino F and Zaffaroni N: Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 25:1129-1136,2004.
66. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K and Kurisu K: Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97: 1077-1083, 2003.
67. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ and Borden EC: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11: 915-923, 2004.
68. Pennati M, Colella G, Folini M, Citti L, Daidone MG and Zaffaroni N: Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 109: 285-286, 2002.